key: cord-0327343-mmw2uy3e authors: Salvucci, Manuela; Crawford, Nyree; Stott, Katie; Bullman, Susan; Longley, Daniel B.; Prehn, Jochen H.M. title: Patients with mesenchymal tumours and high Fusobacteriales prevalence have worse prognosis in colorectal cancer (CRC) date: 2021-05-18 journal: bioRxiv DOI: 10.1101/2021.05.17.444326 sha: 87a2b168453979cc900f6cbf5e3ceeefeff679e8 doc_id: 327343 cord_uid: mmw2uy3e Objective Transcriptomic-based subtyping, Consensus Molecular Subtyping (CMS) and CRC Intrinsic Subtyping (CRIS), identify a patient subpopulation with mesenchymal traits (CMS4/CRIS-B) and poorer outcome. Here, we investigated the relationship between prevalence of Fusobacterium nucleatum (Fn) and Fusobacteriales, CMS/CRIS subtyping, cell type composition, immune infiltrates and host contexture to refine patients stratification and identify druggable context-specific vulnerabilities. Design We coupled cell culture experiments with characterization of Fn/Fusobacteriales prevalence and host biology/microenviroment in tumours from 2 independent CRC patient cohorts (Taxonomy: n=140; TCGA-COAD-READ: n=605). Results In vitro, Fn infection induced inflammation via NFκB/TNFα in HCT116 and HT29 cancer cell lines. In patients, high Fn/Fusobacteriales were found in CMS1, MSI tumours, with infiltration of macrophages M1, reduced macrophages M2, and high IL6/IL8/IL1β signaling. Analysis of the Taxonomy cohort suggested that Fn was prognostic for CMS4/CRIS-B patients, despite having lower Fn load than CMS1 patients. In the TCGA-COAD-READ cohort, we likewise identified a differential association between Fusobacteriales relative abundance and outcome when stratifying patients in mesenchymal (either CMS4 and/or CRIS-B) vs. non-mesenchymal (neither CMS4 nor CRIS-B). Patients with mesenchymal tumours and high Fusobacteriales had approximately 2-fold higher risk of worse outcome. These associations were null in non-mesenchymal patients. Modelling the 3-way association between Fusobacteriales prevalence, molecular subtyping, and host contexture with logistic models with an interaction term disentangled the pathogen/host-signaling relationship and identified aberrations (including EMT/WNT/NOTCH) as candidate targets. Conclusion This study identifies CMS4/CRIS-B patients with high Fn/Fusobacteriales prevalence as a high-risk subpopulation that may benefit from therapeutics targeting mesenchymal biology. Significance of this study What is already known on this subject? Fusobacterium nucleatum (Fn), a commensal Gram-negative anaerobe from the Fusobacteriales order, is an onco-bacterium in CRC as a causal relationship between Fn prevalence and CRC pathogenesis, progression and treatment response has been reported in vivo. Broad spectrum antibiotics has proven moderately successful in reducing tumour growth in preclinical models. However, the use of antibiotics to treat bacterium-positive cases in the clinic is not a viable option as it may further alter the already dysbiotic gut microbiome of CRC patients and may also have limited efficacy against Fn which penetrates and embeds deeply within the tumour. The highly heterogenous CRC patient population can be classified into distinct molecular subtypes (CMS and CRIS) based on gene expression profiles mirroring the underlying transcriptional programs. Patients classified as CMS4 and CRIS-B exhibit a mesenchymal phenotype and have poorer outcome. What are the new findings? Fn/Fusobacteriales prevalence is associated with immune involvement (decrease in macrophages M1 and increase in macrophages M2) and activation of specific signalling programs (inflammation, DNA damage, WNT, metastasis, proliferation, cell cycle) in the host tumours. The prevalence of bacteria from the Fusobacteriales order, largely driven by Fn species, play an active or opportunistic role depending on the underlying host tumour biology and microenvironment. Fn and other species of the Fusobacteriales order are enriched in CMS1 (immuno, microsatellite unstable) patients compared to CMS2-4 cases. Fn/Fusobacteriales prevalence is associated with worse clinical outcome in patients with mesenchymal-rich CMS4/CRIS-B tumours, but not in patients with other molecular subtypes. How might it impact on clinical practice in the foreseeable future? Fn/Fusobacteriales screening and transcriptomic-based molecular subtyping should be considered to identify patients with mesenchymal-rich tumours and high bacterium prevalence and to inform disease management. Fn/Fusobacteriales prevalence may need to be addressed exclusively in patients with mesenchymal-rich high-stromal infiltrating tumours rather than a blanket-approach to treat all pathogen-positive patients. Clinical management of the disease for this subpopulation of high-risk patients with unfavourable clinical outcome could be attained by administering compounds currently in clinical trials that target aberrations in the host signaling pathways (NOTCH, WNT, EMT) and tumour microenviroment (inflammasome, activated T cells, complement system, and macrophage chemotactism and activation). • Fusobacterium nucleatum (Fn), a commensal Gram-negative anaerobe from the Fusobacteriales 49 order, is an onco-bacterium in CRC as a causal relationship between Fn prevalence and CRC 50 pathogenesis, progression and treatment response has been reported in vivo. • Broad spectrum antibiotics has proven moderately successful in reducing tumour growth in 52 preclinical models. However, the use of antibiotics to treat bacterium-positive cases in the clinic is • Fn/Fusobacteriales prevalence may need to be addressed exclusively in patients with mesenchymal-78 rich high-stromal infiltrating tumours rather than a blanket-approach to treat all pathogen-positive 79 patients. • Clinical management of the disease for this subpopulation of high-risk patients with unfavourable 81 clinical outcome could be attained by administering compounds currently in clinical trials that target 82 aberrations in the host signaling pathways (NOTCH, WNT, EMT) and tumour microenviroment Suppl. Fig. 1) . 166 Next, we sought to validate and build upon our findings from the in-house Taxonomy cohort by 167 analyzing the TCGA-COAD-READ cohort (Fig. 2F) . At the transcription level, we confirmed an 168 exacerbated inflammatory state when comparing Fusobacteriales-high and -low patients mediated by 169 the NFκB-TNFα axis, IFNγ with cytolytic involvement. Fusobacteriales-high patients overexpressed 170 pro-inflammatory interleukins (IL6, IL8, IL10, IL1β), cytokines/chemokines (CCL8, ICAM1), metallo-171 proteinases (MMP1, MMP3), NOS2 and inflammasome markers (NLRP3), (Fig. 2F) . 172 As inflammation is strongly tied to immune cell migration and activity, we next investigated whether high Fn load (Taxonomy) or Fusobacteriales (TCGA-COAD-READ) showed higher predicted 180 abundance of regulatory T cells (T regs) coupled with an increase in M1 macrophages and decrease in 181 M2 macrophages (Fig. 2I) . MCP-counter identified a strong positive association between neutrophil 182 infiltration and either Fn load (Taxonomy) or Fusobacteriales RA (TCGA-COAD-READ), (Fig. 2I) . 183 However, no difference in predicted neutrophils abundance was detected by quanTIseq. Importantly, 184 no difference in fibroblasts and endothelial cells was observed by Fn/Fusobacteriales in either cohort 185 by either method (Fig. 2I) . We next leverage the rich molecular characterization of the TCGA-COAD-READ cohort to perform a 190 systematic and unbiased characterization of the association between Fusobacteriales RA and patient 191 clinical and molecular features to identify human host vulnerabilities that may be conducive for tumour 192 development (Fig. 3) . 193 We observed higher Fusobacteriales in patients of older age, diagnosed with more advanced disease 194 stage and tumours located in the colon, particularly in proximal sites, (Fig 3A) , corroborating studies 195 assessing Fn [13] . In contrast, we found no statistically significant differences in Fusobacteriales RA 196 by sex, body mass index and neither lymphovascular nor perineural invasion (Sup. Fig. 2) . 197 Patients harbouring higher Fusobacteriales showed lower genomic intra-tumour heterogeneity, had 198 higher silent and non-silent mutational burden and were enriched in microsatellite unstable cases, (Fig 199 3B) . Fusobacteriales-high patients showed an increase in transitions, defined as the exchange of two-200 ring purines (A↔G) or of a one-ring pyrimidines (C↔T), coupled with a decrease in transversions, a 201 substitution of purine for pyrimidine bases (Suppl. Fig. 3A ) as evidenced by a decrease in conversion 202 changes of C>G and T>A, (Suppl. Fig. 3B ). We found no difference in prevalence of common 203 mutations in CRC by Fusobacteriales (high vs. low) except for BRAF (Fig. 3C) . BRAF mutations 204 trended to be more common among Fusobacteriales-high patients, as observed when assessing Fn [13] . were more prevalent in Fusobacteriales-high patients, (Fig. 3D , Suppl. Table 2) . 208 Next, we set out to investigate the relationship between copy number alterations (CNAs) and 209 Fusobacteriales presence in the TCGA-COAD-READ cohort ( Fig. 3E-G) . We determined recurrent Table 3) . Fusobacteriales-high cases showed lower chromosomal 212 instability with a lower fraction of the genome affected by recurrent CNAs, in line with their MSI 213 unstable status. Next, we identified CNA amplifications (in red) or deletions (in blue) whose frequency 214 of occurrence differed when comparing Fusobacteriales-high vs. -low patients and thus may be 215 specifically associated with the bacterium presence (Fig. 3F) . CNAs more frequently (>15%) observed 216 in Fusobacteriales-high vs. low cases included deletions in 8p23.2 (tumour suppressor CSMD1 and 217 LOC100287015); 18q21.1 (MIR4743 and RNA binding by CTIF) and 18q23 which impacts the 218 regulation of interleukin-6 and chemokine secretion, cell-cell adhesion and host of viral transcription, 219 as determined by enrichment analyses carried out with EnrichR, (Fig. 3G) . 220 We then focused on the transcriptional level and we combined enrichment analyses with pathway-221 activity signatures to compare cellular processes by Fusobacteriales RA (Fig. 3H Sup. Fig. 6 and Sup. Table 4 ). We corroborated these findings by comparing the activation of Next, we sought to investigate whether the findings at the genomic and transcriptional level were also 231 observed in protein profiles determined by Reverse Phase Protein Array (RPPA). We found a 232 differential expression by Fusobacteriales RA for proteins involved in microenvironment composition 233 Fig. 4A ) and 241 Fusobacteriales RA (TCGA-COAD-READ, Fig. 4C ) in CMS1 tumours, corroborating the interplay 242 between pathogen prevalence and host immunity. Moreover, we observed higher Fn load in CRIS-B 243 tumours (Fig. 4B) and Fusobacteriales RA in CRIS-A cases (Fig. 4D) of the Taxonomy and TCGA-244 COAD-READ cohorts, respectively. At the family rank, Fusobacteriaceae were more abundant than 245 Leptotrichiaceae accounting for 77% and 23% of total Fusobacteriales RA and ~2% and ~<1% of the 246 total bacteria RA, respectively. In line with the findings at the order level, we observed an increase in 247 Fn, the most abundant Fusobacterium species, in CMS1 and CRIS-A cases ( Fig. 4E-F) . In line with 248 the findings at the order level, we observed an approximately 3-fold increase when comparing patients 249 classified as CMS1 vs. the rest (Fig 4E) . Fn, the most abundant Fusobacterium species, was enriched 250 in CMS1 and CRIS-A cases (Fig. 4E-F) . Next, we examined whether the positive association between 251 inflammation and immune involvement by Fn/Fusobacteriales presence could be ascribed to the host 252 CMS1 milieu or whether there was an additional pathogen-induced component. When restricting the 253 analysis to CMS1 cases, we observed higher expression of pro-inflammatory markers in 254 Fusobacteriales-high patients of the TCGA-COAD-READ cohort. We detected no association between 255 pathogen prevalence and expression of anti-inflammatory markers or inflammation signatures in 256 neither CRC cohorts (Fig. 4G-H) . Taken together these results suggest that Fn/Fusobacteriales may 257 play an active role in mediating inflammation in the host. Next, we sought to investigate whether bacterium presence correlated with patient clinical outcome 261 assessed by overall-(OS), disease-specific-(DSS) and disease-free-(DFS) survival endpoints (Fig. 5 262 and Suppl. Figs. 8-10) . We found no statistically significant differences in neither cohort when comparing survival curves from 264 patients grouped by either Fn load or Fusobacteriales RA (Fig. 5A, E, I and Suppl. Figs. 8-10) . We 265 hypothesized that Fn/Fusobacteriales may result in poorer outcome in a subtype-dependent context. 266 Indeed, we identified a differential association between Fusobacteriales RA and clinical outcome of 267 the TCGA-COAD-READ cohort in mesenchymal (either CMS4 and/or CRIS-B) vs. non-mesenchymal 268 (neither CMS4 nor CRIS-B) tumours, (Fig. 5G, H, K, L and Sup. Figs. 8-10) . Fusobacteriales-high 269 mesenchymal patients had approximately 2-fold higher risk of worse outcome while these associations 270 were null in non-mesenchymal patients (Fig. 5G, H, K, L and Sup. Figs. 8-10) . 271 Although numbers in the Taxonomy cohort are limited, when restricting the analysis to CMS4 and/or 272 CRIS-B cases, we observed a trend whereby Fn-high patients had shorter OS than those with low Fn 273 load. Again, no difference in survival curves by Fn load was observed in non-mesenchymal Taxonomy 274 patients (Fig. 5C-D) . 275 Exploratory analyses examining the association between clinical outcome and pathogen prevalence at 276 taxonomic ranks of increasing resolution (order, family, genus and species) in the TCGA-COAD-277 READ cohort by fitting Cox regression models on the whole unselected population and in 278 mesenchymal vs. non-mesenchymal settings revealed that the prognostic impact stems primarily from, 279 but is not limited to, species, including Fn, from the Fusobacterium genus from the Fusobacteriaceae 280 family ( Fig. 5M and Sup. Fig. 10) . 281 282 We examined the host signaling pathways and microenvironment to identify alterations that may be 284 mediated by and/or exacerbated by Fusobacteriales (i.e. interact) and, thus, may promote virulence 285 and, ultimately, result in an unfavorable clinical outcome. To disentangle the 3-way association 286 between Fusobacteriales RA, gene/signature, and molecular subtyping, we fitted 2 distinct logistic 287 regression models for each feature of interest in the TCGA-COAD-READ cohort. The selection of 288 features was hypothesis-driven and included key host signaling pathways and immuno-modulators 289 (Fig. 6A) . 290 identifies a set of genes/signatures whose expression patterns differ by molecular subtype (statistically 295 significant interaction p-value in model 2) and thus may be mediating the pathogenic impact of 296 Fusobacteriales and were prioritized for downstream analyses (Fig. 6B) . 297 NOTCH, EMT, TIS score, IL6, CSF1 are among the genes/signatures identified by model 2 in Fig. 6A 298 whose expression profiles track with molecular subtyping and may represent druggable vulnerabilities 299 in patients with mesenchymal tumours and high Fn/Fusobacteriales prevalence and ameliorate clinical 300 outcome (Fig. 6B ). Fusobacteriales, predominantly Fn, have been associated [5] with pathogenesis, progression and 303 treatment response in CRC. We coupled mechanistic studies in cell cultures with hypothesis-driven and 304 unbiased screening in clinically-relevant and 'omics-rich CRC cohorts to examine the cross-talk 305 between pathogen-host and pathogen-tumour microenvironment. We demonstrated relationships 306 between Fn/Fusobacteriales prevalence with host immune, signaling activation and transcriptomic-307 based molecular subtypes. Our findings suggest that host-pathogen interactions can define patient sub-308 populations where Fn/Fusobacteriales play an active or opportunistic role depending on the underlying 309 host tumour biology and microenvironment and identify putative druggable and clinically-actionable 310 We observed higher Fn/Fusobacteriales prevalence in CMS1 patients, corroborating findings by 312 Purcell [28] . Interestingly, we found that higher pathogen prevalence did not correlate with poorer 313 disease outcome. In contrast, Fn/Fusobacteriales virulence was exacerbated in CMS4/CRIS-B patients, 314 suggesting that pathogen persistence may need addressing exclusively in mesenchymal-rich high- Given that "it takes two to tango", namely a high pathogen prevalence and a conducive host milieu, we 322 further examined this interdependence to identify druggable aberrations in the host signaling pathways 323 and microenvironment. We identified putative targets related to (pro-)inflammation, inflammasome, 324 activated T cells, complement system, metallo-proteins and macrophage chemotaxis and activation. 325 Fn/Fusobacteriales prevalence, corroborating findings from Casasanta assessing Fn in HCT116 CRC 376 cells [54] . 377 In conclusion, our analyses have identified a patient sub-population that has an unfavorable clinical 378 outcome when their tumours exhibit mesenchymal traits and are highly positive with Fn/Fusobacteriales and pinpointed clinically-actionable host-specific vulnerabilities that suggest new 380 treatments for these patients that extend beyond broad spectrum antibiotics. 381 Detailed methods for the in vitro cell culture experiments and the study design, cohorts description and 383 analysis steps are provided in the online supplementary materials and methods. 384 385 Patients or the public were not involved in the design, recruitment, conduct, reporting and 387 dissemination of this research. 388 389 Processing and analysis code along with pathogen prevalence with corresponding clinical and 391 molecular datasets for the Taxonomy and TCGA-COAD-READ cohorts included in this study will be 392 made publicly available and archived upon publication at Zenodo (https://10.5281/zenodo.4019142). 393 Pathogen prevalence will include Fusobacterium nucleatum load and Fusobacteriales relative 394 abundance (along with higher resolution estimates at genus, family and species taxonomic rank) for the 395 Taxonomy and TCGA-COAD-READ cohorts, respectively. 396 397 We wish to thank the patients who kindly donated their samples and made this study possible. This Global cancer statistics 2018: GLOBOCAN estimates of 525 incidence and mortality worldwide for 36 cancers in 185 countries Epithelial-to-mesenchymal transition signature 575 assessment in colorectal cancer quantifies tumour stromal content rather than true transition Nbt.1868.Pdf GATK PathSeq: a customizable computational tool 579 for the discovery and identification of microbial sequences in libraries from eukaryotic hosts Molecular and pharmacological modulators of the tumor 582 immune contexture revealed by deconvolution of RNA-seq data Estimating the population abundance of tissue-infiltrating 585 immune and stromal cell populations using gene expression Microbiota profile and impact of 588 fusobacterium nucleatum in colorectal cancer patients of barretos cancer hospital. Frontiers in 589 0 facilitates sensitive and confident localization 591 of the targets of focal somatic copy-number alteration in human cancers Fusobacterium nucleatum persistence and risk of recurrence 594 after preoperative treatment in locally advanced rectal cancer Distinct gut microbiome patterns associate with consensus 597 molecular subtypes of colorectal cancer Intracellular degradation of fusobacterium nucleatum in human 599 gingival epithelial cells Utilizing whole fusobacterium genomes to identify, correct, 601 and characterize potential virulence protein families Treating inflammation by blocking interleukin-1 in a 606 broad spectrum of diseases Periodontal therapy reduces the severity of active rheumatoid 608 arthritis in patients treated with or without tumor necrosis factor inhibitors Translating IL-6 biology into effective treatments Breast cancer colonization by Fusobacterium nucleatum 613 accelerates tumor growth and metastatic progression Cancer-associated fibroblasts are activated in incipient neoplasia to 616 orchestrate tumor-promoting inflammation in an nf-kappaB-dependent manner The aurora kinase beta-catenin axis contributes to dexamethasone 619 resistance in leukemia Antitumor activity of the aurora a selective kinase 621 inhibitor, alisertib, against preclinical models of colorectal cancer Small molecule inhibitors of aurora-a induce proteasomal 624 degradation of n-myc in childhood neuroblastoma Non-redundant functions of EMT transcription factors The matrix in cancer Highly invasive melanoma cells activate the vascular 631 endothelium via an MMP-2/integrin alpha beta induced secretion of vegf-a. The American Journal of 632 Human brain endothelial cell-derived cox-2 facilitates 634 extravasation of breast cancer cells across the bloodbrain barrier Matrix metalloproteinase inhibitors in cancer therapy: Turning past 637 failures into future successes A phase 3 randomized, double-blind, placebo-controlled 640 study to evaluate the efficacy and safety of GS-5745 combined with mFOLFOX6 as first-line treatment 641 in patients with advanced gastric or gastroesophageal junction adenocarcinoma Association of dietary patterns with risk of colorectal cancer 644 subtypes classified by fusobacterium nucleatum in tumor tissue Targeting the MAPK7/MMP9 axis for metastasis in primary bone 647 cancer Stromal microenvironment shapes the intratumoral 649 architecture of pancreatic cancer A phase II study of RO4929097 in metastatic colorectal 651 cancer Reshaping prostate tumor microenvironment to suppress metastasis via 653 cancer-associated fibroblast inactivation with peptide-assembly-based nanosystem TGF-beta drives immune evasion in genetically 656 reconstituted colon cancer metastasis An oncolytic virus expressing a t-cell engager 658 simultaneously targets cancer and immunosuppressive stromal cells Cancer-associated fibroblasts: Overview, progress, challenges, and 661 directions Fusobacterium nucleatum host-cell binding and 664 invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration A. Schematic representation of the cohorts included in the study and methods to estimate Fn load and 425 Fusobacteriales (order) relative abundance in the Taxonomy and TCGA-COAD-READ cohorts, 426 respectively.